Overview

Tolerability and Safety of Duloxetine BID in Healthy Female Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the safety and tolerability of 100 mg of duloxetine BID compared to 40 mg of duloxetine BID or placebo for 7 days
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Duloxetine Hydrochloride